PDBCode	numPep	title	KeyWords	depDate	releaseDate	expTech	PDBAuthor	refAuthors	refTitle	reference	hetAtoms	Crystallization	Resolution	RFree	RObsv	SpaceGroup	UnitCell	z	seq	len	chainID	molName	numPerCell	EXPRESSION_SYSTEM	ORGANISM_SCIENTIFIC	chainAnno	processNotes
1MUI	1	CRYSTAL STRUCTURE OF HIV-1 PROTEASE COMPLEXED WITH LOPINAVIR.	HYDROLASE	23-SEP-02	23-OCT-02	X-RAY DIFFRACTION	V.STOLL;W.QIN;K.D.STEWART;C.JAKOB;C.PARK;K.WALTER;R.L.SIMMER;R.HELFRICH;D.BUSSIERE;J.KAO;D.KEMPF;H.L.SHAM;D.W.NORBECK	V.STOLL;W.QIN;K.D.STEWART;C.JAKOB;C.PARK;K.WALTER;;R.L.SIMMER;R.HELFRICH;D.BUSSIERE;J.KAO;D.KEMPF;;H.L.SHAM;D.W.NORBECK	X-RAY CRYSTALLOGRAPHIC STRUCTURE OF ABT-378 (LOPINAVIR) BOUND TO HIV-1 PROTEASE	BIOORG.MED.CHEM. V. 10 2803 2002	1:AB1	100MM NA ACETATE, 0.4-0.8M NACL, PH 4.6, TEMPERATURE 295K	2.80	0.329	0.309	P 61	63.26*63.26*83.62(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	B;A	PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q903J0_9HIV1:Q903J0:57-155	
1RV7	1	CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HIV-1 PROTEASE REVEAL AN EXPANDED ACTIVE SITE CAVITY	HIV PROTEASE;AIDS;POLYPROTEIN;HYDROLASE;ASPARTYLPROTEASE;MULTI-DRUG RESISTANCE;LOPINAVIR	12-DEC-03	14-DEC-04	X-RAY DIFFRACTION	B.C.LOGSDON;J.F.VICKREY;P.MARTIN;G.PROTEASA;J.I.KOEPKE;S.R.TERLECKY;Z.WAWRZAK;M.A.WINTERS;T.C.MERIGAN;L.C.KOVARI	B.C.LOGSDON;J.F.VICKREY;P.MARTIN;G.PROTEASA;;J.I.KOEPKE;S.R.TERLECKY;Z.WAWRZAK;M.A.WINTERS;;T.C.MERIGAN;L.C.KOVARI	CRYSTAL STRUCTURES OF A MULTIDRUG-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE REVEAL AN EXPANDED ACTIVE-SITE CAVITY.	J.VIROL. V. 78 3123 2004	1:AB1	MES, SODIUM CHLORIDE, PH 6.7, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 295K	2.70	0.350	0.271	P 41	44.98*44.98*103.68(90.00x90.00x90.00)	8	PQITLWQRPIVTIKIGGQLKEALLNTGADDTVLEEVNLPGRWKPKLIGGIGGFVKVRQYDQVPIEICGHKVIGTVLVGPTPANVIGRNLMTQIGCTLNF	99	A;B	PROTEASE	2	Escherichia coli bl21(de3)	Human immunodeficiency virus 1	Q9QM22_9HIV1:Q9QM22:1-99	
2O4S	1	CRYSTAL STRUCTURE OF HIV-1 PROTEASE (Q7K) IN COMPLEX WITH LOPINAVIR	PROTEASE;VIRAL PROTEIN	04-DEC-06	12-DEC-06	X-RAY DIFFRACTION	A.A.ARMSTRONG;S.MUZAMMIL;A.JAKALIAN;P.R.BONNEAU;V.SCHMELMER;E.FREIRE;L.M.AMZEL	S.MUZAMMIL;A.A.ARMSTRONG;L.W.KANG;A.JAKALIAN;P.R.BONNEAU;;V.SCHMELMER;L.M.AMZEL;E.FREIRE	UNIQUE THERMODYNAMIC RESPONSE OF TIPRANAVIR TO HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE DRUG RESISTANCE MUTATIONS.	J.VIROL. V. 81 5144 2007	1:AB1; 4:CL; 2:GOL	1.5 M NACL, 100 MM CITRATE BUFFER PH 5.4-5.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.54	0.215	0.184	P 21 21 2	59.71*85.42*46.23(90.00x90.00x90.00)	8	PQITLWKRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMIGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	A;B	PROTEASE	2	Escherichia coli bl21(de3)	Human immunodeficiency virus 1	POL_HV1BR:P03367:500-598	
2Q5K	1	CRYSTAL STRUCTURE OF LOPINAVIR BOUND TO WILD TYPE HIV-1 PROTEASE	DRUG DESIGN;HIV-1 PROTEASE;PROTEASE INHIBITORS;HYDROLASE	01-JUN-07	04-SEP-07	X-RAY DIFFRACTION	C.A.SCHIFFER;M.N.L.NALAM	G.S.REDDY;A.ALI;M.N.NALAM;S.G.ANJUM;H.CAO;R.S.NATHANS;;C.A.SCHIFFER;T.M.RANA	DESIGN AND SYNTHESIS OF HIV-1 PROTEASE INHIBITORS INCORPORATING OXAZOLIDINONES AS P2/P2' LIGANDS IN PSEUDOSYMMETRIC DIPEPTIDE ISOSTERES.	J.MED.CHEM. V. 50 4316 2007	1:AB1; 4:PO4	126MM SODIUM PHOSPHATE, 63MM SODIUM CITRATE, 24-29% AMMONIUM SULPHATE, PH 6.2, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.95	0.236	0.194	P 21 21 21	51.34*58.04*61.13(90.00x90.00x90.00)	8	PQITLWKRPLVTIRIGGQLKEALLDTGADDTVLEEMNLPGKWKPKMIGGIGGFIKVRQYDQIPIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	A;B	PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	O38732_9HIV1:O38732:1-99	
2QHC	1	THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR	HIV PROTEASE INHIBITORS; PROTEASE-INHIBITOR STRUCTURE;ASPARTIC PROTEASE;RESISTANT STRAIN;HYDROLASE	02-JUL-07	22-JUL-08	X-RAY DIFFRACTION	J.BRYNDA;K.G.SASKOVA;M.KOZISEK;M.LEPSIK;L.MACHALA;J.KONVALINKA	K.G.SASKOVA;M.KOZISEK;M.LEPSIK;J.BRYNDA;P.REZACOVA;;J.VACLAVIKOVA;R.M.KAGAN;L.MACHALA;J.KONVALINKA	ENZYMATIC AND STRUCTURAL ANALYSIS OF THE I47A MUTATION CONTRIBUTING TO THE REDUCED SUSCEPTIBILITY TO HIV PROTEASE INHIBITOR LOPINAVIR.	PROTEIN SCI. V. 17 1555 2008	1:AB1; 2:BME	0.5M (NH4)2SO4, 0.1M MES PH 5.4 OR PH 5.5, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	2.80	0.228	0.193	P 61	62.58*62.58*81.93(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMAGGIGGFIKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	A;B	PROTEASE RETROPEPSIN	2	Escherichia coli	Human immunodeficiency virus 1	POL_HV1BR:P03367:69-167	
2RKF	1	HIV-1 PR RESISTANT MUTANT + LPV	RESISTENCE;INSERTION;HYDROLASE	16-OCT-07	05-AUG-08	X-RAY DIFFRACTION	P.REZACOVA;J.BRYNDA;M.KOZISEK;K.G.SASKOVA;J.KONVALINKA	M.KOZISEK;K.G.SASKOVA;P.REZACOVA;J.BRYNDA;;N.M.VAN;M.NIJHUIS;J.KONVALINKA	NINETY-NINE IS NOT ENOUGH: MOLECULAR CHARACTERIZATION OF INHIBITOR-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE MUTANTS WITH INSERTIONS IN THE FLAP REGION	J.VIROL. V. 82 5869 2008	1:AB1; 2:GOL; 2:SO4	RESERVOIR: 0.1M MES PH 5.4, 0.5M AMMONIUM SULFATE; DROPS: 2UL PROTEIN + 1UL RESERVOIR CPR=8MG/ML, 5-FOLD MOLAR EXCESS OF LPV , VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298.0K	1.80	0.248	0.194	P 61	61.96*61.96*84.11(90.00x90.00x120.00)	12	PQITLWQRPFVTVKIAGQLMEALLDTGADDTILEEMSLPGRWTPKVVGGIGGFMKVRQYDQILVEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF	99	A;B	PROTEASE RETROPEPSIN	2	Escherichia coli	Human immunodeficiency virus 1	A0F7J4_9HIV1:A0F7J4:1-99	
2RKG	1	HIV-1 PR RESISTANT MUTANT + LPV	RESISTENCE;INSERTION;HYDROLASE	16-OCT-07	05-AUG-08	X-RAY DIFFRACTION	P.REZACOVA;J.BRYNDA;M.KOZISEK;K.SASKOVA;J.KONVALINKA	M.KOZISEK;K.G.SASKOVA;P.REZACOVA;J.BRYNDA;;N.M.VAN;M.NIJHUIS;J.KONVALINKA	NINETY-NINE IS NOT ENOUGH: MOLECULAR CHARACTERIZATION OF INHIBITOR-RESISTANT HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 PROTEASE MUTANTS WITH INSERTIONS IN THE FLAP REGION	J.VIROL. V. 82 5869 2008	1:AB1; 2:GOL	RESERVOIR: 0.1M MES PH 5.5, 0.5M AMMONIUM SULFATE; DROPS: 2UL PROTEIN + 1UL RESERVOIR CPR=8MG/ML, 5-FOLD MOLAR EXCESS OF LPV MICROSEEDING, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.80	0.249	0.195	P 61	62.01*62.01*83.94(90.00x90.00x120.00)	12	PQITLWQRPFVTVKIAGQLMEALLDTGADDTILEEEMSLPGRWTPKVVGGIGGFMKVRQYDQILVEICGHKVIGTVLVGPTPANIIGRNLLTQIGCTLNF	100	A;B	PROTEASE RETROPEPSIN	2	Escherichia coli	Human immunodeficiency virus 1	A0F7J4_9HIV1:A0F7J4:1-99	
2Z54	1	THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR	COMPLEX (ASPARTIC PROTEASE/INHIBITOR);ASPARTIC PROTEASE;RESISTANT STRAIN;HYDROLASE	28-JUN-07	01-JUL-08	X-RAY DIFFRACTION	J.BRYNDA;S.KLARA;M.KOZISEK;M.LEPSIK;L.MACHALA;J.KONVALINKA	S.KLARA;J.BRYNDA;M.KOZISEK;M.LEPSIK;L.MACHAL;;J.KONVALINKA	THE INFLUENCE OF I47A MUTATION ON REDUCED SUSCEPTIBILITY TO THE PROTEASE INHIBITOR LOPINAVIR	TO BE PUBLISHED	1:AB1; 2:BME	NULL	2.31	0.254	0.202	P 61	62.25*62.25*82.15(90.00x90.00x120.00)	12	PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMSLPGRWKPKMAGGIGGFVKVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLNF	99	A;B	HIV-1 PROTEASE	2	Escherichia coli	Human immunodeficiency virus type 1	POL_HV1B5:P04587:501-599	
3OGQ	1	CRYSTAL STRUCTURE OF 6S-98S FIV PROTEASE WITH LOPINAVIR BOUND	ASPARTYL PROTEASE;HIV-LIKE FIV CHIMERA;HYDROLASE-HYDROLASEINHIBITOR COMPLEX	17-AUG-10	08-JUN-11	X-RAY DIFFRACTION	Y.-C.LIN;A.L.PERRYMAN;J.H.ELDER;C.D.STOUT	Y.C.LIN;A.L.PERRYMAN;A.J.OLSON;B.E.TORBETT;J.H.ELDER;;C.D.STOUT	STRUCTURAL BASIS FOR DRUG AND SUBSTRATE SPECIFICITY EXHIBITED BY FIV ENCODING A CHIMERIC FIV/HIV PROTEASE.	ACTA CRYSTALLOGR.,SECT.D V. 67 540 2011	1:AB1; 2:DMS	VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 277K	1.80	0.279	0.228	P 31	81.79*81.79*33.94(90.00x90.00x120.00)	6	YNKVGTTTTLEKRPEILIFVNGYPIKFLLDTGADITVLNRRDFQVKNSIENGRQMMIGIGGGKRGTNYINVHLEIRDENYKTQCIFGNVCVLEDNSLSVNLLGRDNMIKFNIRLVM	116	A;B	FIV PROTEASE	2	Escherichia coli	Feline immunodeficiency virus	POL_FIVPE:P16088:39-154	
4L1A	2	CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE	HIV-1 PROTEASE;MULTI-DRUG RESISTANCE;IC50;LOPINAVIR;PROTEASE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	03-JUN-13	02-APR-14	X-RAY DIFFRACTION	Z.LIU;R.S.YEDIDI;Y.WANG;T.DEWDNEY;S.REITER;J.BRUNZELLE;I.KOVARI;L.KOVARI	Z.LIU;R.S.YEDIDI;Y.WANG;T.G.DEWDNEY;S.J.REITER;;J.S.BRUNZELLE;I.A.KOVARI;L.C.KOVARI	CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE.	BIOCHEM.BIOPHYS.RES.COMMUN. V. 437 199 2013	1:AB1	THE HANGING DROP VAPOR DIFFUSION METHOD WAS USED TO FORM THE BIPYRAMIDAL CRYSTALS OF THE MDR 769 PROTEASE. USING A GRID SCREEN CONSISTING OF SODIUM CHLORIDE (0.7 TO 1.4 M) AND MES-HEPES BUFFER (PH 5.5 TO 8.1), THE HIV-1 PROTEASE SUBSTRATE COMPLEX CRYSTALS FORMED OVERNIGHT AT 22 C. ROUTINELY, 0.2 MM CRYSTALS, IN THE LONGEST DIMENSION, WERE OBTAINED AFTER 14 DAYS OF INCUBATION. IN EACH WELL, THERE WERE TWO DROPLETS, CONTAINING 1 LL OF PROTEASE SUBSTRATE MIXTURE, 1 LL OF RESERVOIR SOLUTION AND 2 LL OF PROTEASE SUBSTRATE MIXTURE, 1 LL OF RESERVOIR SOLUTION, RESPECTIVELY, 07 ML OF WELL SOLUTION., VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.90	0.260	0.201	P 41	43.83*43.83*101.81(90.00x90.00x90.00)	4	PQITLWQRPIVTIKIGGQLKEALLNTGADDTVLEEVNLPGRWKPKLIGGIGGFVKVRQYDQVPIEICGHKTIGTVLVGPTPTNVIGRNLMTQIGCTLNF	99	B	MDR769 HIV-1 PROTEASE	1	Escherichia coli	Human immunodeficiency virus 1	Q000H7_9HIV1:Q000H7:1-99	
4L1A	2	CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE	HIV-1 PROTEASE;MULTI-DRUG RESISTANCE;IC50;LOPINAVIR;PROTEASE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	03-JUN-13	02-APR-14	X-RAY DIFFRACTION	Z.LIU;R.S.YEDIDI;Y.WANG;T.DEWDNEY;S.REITER;J.BRUNZELLE;I.KOVARI;L.KOVARI	Z.LIU;R.S.YEDIDI;Y.WANG;T.G.DEWDNEY;S.J.REITER;;J.S.BRUNZELLE;I.A.KOVARI;L.C.KOVARI	CRYSTALLOGRAPHIC STUDY OF MULTI-DRUG RESISTANT HIV-1 PROTEASE LOPINAVIR COMPLEX: MECHANISM OF DRUG RECOGNITION AND RESISTANCE.	BIOCHEM.BIOPHYS.RES.COMMUN. V. 437 199 2013	1:AB1	THE HANGING DROP VAPOR DIFFUSION METHOD WAS USED TO FORM THE BIPYRAMIDAL CRYSTALS OF THE MDR 769 PROTEASE. USING A GRID SCREEN CONSISTING OF SODIUM CHLORIDE (0.7 TO 1.4 M) AND MES-HEPES BUFFER (PH 5.5 TO 8.1), THE HIV-1 PROTEASE SUBSTRATE COMPLEX CRYSTALS FORMED OVERNIGHT AT 22 C. ROUTINELY, 0.2 MM CRYSTALS, IN THE LONGEST DIMENSION, WERE OBTAINED AFTER 14 DAYS OF INCUBATION. IN EACH WELL, THERE WERE TWO DROPLETS, CONTAINING 1 LL OF PROTEASE SUBSTRATE MIXTURE, 1 LL OF RESERVOIR SOLUTION AND 2 LL OF PROTEASE SUBSTRATE MIXTURE, 1 LL OF RESERVOIR SOLUTION, RESPECTIVELY, 07 ML OF WELL SOLUTION., VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.90	0.260	0.201	P 41	43.83*43.83*101.81(90.00x90.00x90.00)	4	PQITLWQRPIVTIKIGGQLKEALLNTGADDTVLEEVNLPGRWKPKLIGGIGGFVKVRQYDQVPIEICGHKVIGTVLVGPTPTNVIGRNLMTQIGCTLNF	99	A	MDR769 HIV-1 PROTEASE	1	Escherichia coli	Human immunodeficiency virus 1	Q000H7_9HIV1:Q000H7:1-99	
6DJ1	1	WILD-TYPE HIV-1 PROTEASE IN COMPLEX WITH LOPINAVIR	ANTIVIRAL AGENTS;PROTEIN-INHIBITOR STRUCTURES;HIV DRUG RESISTANCE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	24-MAY-18	17-OCT-18	X-RAY DIFFRACTION	Y.-F.WANG;A.E.WONG-SAM;Y.ZHANG;I.T.WEBER	A.WONG-SAM;Y.F.WANG;Y.ZHANG;A.K.GHOSH;R.W.HARRISON;I.T.WEBER	DRUG RESISTANCE MUTATION L76V ALTERS NONPOLAR INTERACTIONS AT THE FLAP-CORE INTERFACE OF HIV-1 PROTEASE.	ACS OMEGA V. 3 12132 2018	1:AB1; 3:CL; 1:NA	1 M NACL, 0.1 M MES, PH 5.6, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.26	N/A	N/A	P 21 21 2	59.73*85.20*46.27(90.00x90.00x90.00)	8	PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEIAGHKAIGTVLVGPTPVNIIGRNLLTQIGATLNF	99	A;B	HIV-1 PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q5RZ08_9HIV1:Q5RZ08:1-99	
6DJ2	1	HIV-1 PROTEASE WITH SINGLE MUTATION L76V IN COMPLEX WITH LOPINAVIR	ANTIVIRAL AGENTS;PROTEIN-INHIBITOR STRUCTURES;HIV DRUG RESISTANCE;HYDROLASE-HYDROLASE INHIBITOR COMPLEX	24-MAY-18	17-OCT-18	X-RAY DIFFRACTION	Y.-F.WANG;A.E.WONG-SAM;Y.ZHANG;I.T.WEBER	A.WONG-SAM;Y.F.WANG;Y.ZHANG;A.K.GHOSH;R.W.HARRISON;I.T.WEBER	DRUG RESISTANCE MUTATION L76V ALTERS NONPOLAR INTERACTIONS AT THE FLAP-CORE INTERFACE OF HIV-1 PROTEASE.	ACS OMEGA V. 3 12132 2018	1:AB1; 3:CL; 1:NA	0.9 M NACL, 5% DMSO, 0.1 M CITRATE PHOSPHATE, PH 6.0, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K	1.36	N/A	N/A	P 21 21 2	60.01*85.38*46.43(90.00x90.00x90.00)	8	PQITLWKRPLVTIKIGGQLKEALLDTGADDTVIEEMSLPGRWKPKMIGGIGGFIKVRQYDQIIIEIAGHKAIGTVVVGPTPVNIIGRNLLTQIGATLNF	99	A;B	HIV-1 PROTEASE	2	Escherichia coli	Human immunodeficiency virus 1	Q5RZ08_9HIV1:Q5RZ08:1-99	
